Abstract | OBJECTIVE: DESIGN: Meta-analysis of results from 16 randomised controlled clinical studies. SUBJECTS: INTERVENTION: MAIN OUTCOME MEASURES: RESULTS: A significant reduction in the incidence of thrombus extension (common odds ratio 0.51, 95% confidence interval 0.32 to 0.83; P = 0.006) in favour of low molecular weight heparin was observed. Non-significant trends also in favour of the low molecular weight heparins were observed for the recurrence of thromboembolic events (0.66, 0.41 to 1.07; P = 0.09), major haemorrhages (0.65, 0.36 to 1.16; P = 0.15), and total mortality (0.72, 0.46 to 1.4; P = 0.16). CONCLUSIONS: Low molecular weight heparins seem to have a higher benefit to risk ratio than unfractionated heparin in the treatment of venous thrombosis. These results, however, remain to be confirmed by using clinical outcomes in suitably powered clinical trials.
|
Authors | A Leizorovicz, G Simonneau, H Decousus, J P Boissel |
Journal | BMJ (Clinical research ed.)
(BMJ)
Vol. 309
Issue 6950
Pg. 299-304
(Jul 30 1994)
ISSN: 0959-8138 [Print] England |
PMID | 8086867
(Publication Type: Comparative Study, Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Heparin, Low-Molecular-Weight
- Heparin
|
Topics |
- Dose-Response Relationship, Drug
- Hemorrhage
(chemically induced)
- Heparin
(adverse effects, therapeutic use)
- Heparin, Low-Molecular-Weight
(adverse effects, therapeutic use)
- Humans
- Incidence
- Odds Ratio
- Pulmonary Embolism
(drug therapy, mortality)
- Randomized Controlled Trials as Topic
- Recurrence
- Thrombophlebitis
(drug therapy, mortality)
|